FIELD: biotechnology.
SUBSTANCE: described is an oncolytic adenoviral vector comprising deletion of a nucleic acid sequence in an E3 region and a nucleic acid sequence, coding bispecific monoclonal antibody, instead of deleted nucleic acid sequence in section E3, where the bispecific monoclonal antibody contains a single-strand variable fragment (scFv) specific to a cell surface molecule on immunological effector cells, and scFv specific to the tumor antigen, wherein the adenoviral vector frame is serotype 5 adenovirus nucleic acid frame (Ad5), and the vector further comprises an Ad3 fiber head.
EFFECT: invention extends the range of cancer treatment agents and adaptive cell therapy.
23 cl, 21 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS | 2009 |
|
RU2520823C2 |
| COATED ONCOLYTIC ADENOVIRUS FOR ANTICANCER VACCINES | 2015 |
|
RU2695375C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| ONCOLYTIC ADENOVIRUS FOR TREATING CANCER, USING IT, AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2010 |
|
RU2536931C2 |
| ADENOVIRUS CONTAINING ALBUMIN-BINDING SITE | 2015 |
|
RU2711371C2 |
| MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
| RECOMBINANT ADENOVIRUS CONTAINING TRANS-SPLICING MEDIATING RIBOZYME, AND ANTI-CANCER THERAPEUTIC GENE, AND USING IT | 2012 |
|
RU2575620C2 |
| CHIMERIC ADENOVIRUSES APPLICABLE FOR TREATING MALIGNANT GROWTH | 2005 |
|
RU2448157C2 |
| ANTICANCER COMPOSITION CONTAINING TUMOR-SPECIFIC ONCOLYTIC ADENO VIRUS AND INHIBITOR OF CONTROL POINT OF IMMUNE RESPONSE | 2018 |
|
RU2777523C2 |
